NO20090305L - Cyklosporin formuleringer - Google Patents
Cyklosporin formuleringerInfo
- Publication number
- NO20090305L NO20090305L NO20090305A NO20090305A NO20090305L NO 20090305 L NO20090305 L NO 20090305L NO 20090305 A NO20090305 A NO 20090305A NO 20090305 A NO20090305 A NO 20090305A NO 20090305 L NO20090305 L NO 20090305L
- Authority
- NO
- Norway
- Prior art keywords
- cyclosporine formulations
- cyclosporine
- formulations
- preparations
- described here
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82023906P | 2006-07-25 | 2006-07-25 | |
US82980806P | 2006-10-17 | 2006-10-17 | |
US82979606P | 2006-10-17 | 2006-10-17 | |
US86945906P | 2006-12-11 | 2006-12-11 | |
US88352507P | 2007-01-05 | 2007-01-05 | |
US91635207P | 2007-05-07 | 2007-05-07 | |
PCT/US2007/074079 WO2008014200A2 (fr) | 2006-07-25 | 2007-07-23 | Compositions de cyclosporine |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090305L true NO20090305L (no) | 2009-02-24 |
Family
ID=38626720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090305A NO20090305L (no) | 2006-07-25 | 2009-01-20 | Cyklosporin formuleringer |
Country Status (11)
Country | Link |
---|---|
US (5) | US9561178B2 (fr) |
EP (2) | EP2043602B1 (fr) |
JP (6) | JP2009544722A (fr) |
KR (1) | KR20090053797A (fr) |
AU (1) | AU2007276815B2 (fr) |
BR (1) | BRPI0714727A2 (fr) |
CA (1) | CA2658518A1 (fr) |
IL (1) | IL196591A0 (fr) |
MX (1) | MX2009000843A (fr) |
NO (1) | NO20090305L (fr) |
WO (1) | WO2008014200A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
AU2016203191B2 (en) * | 2006-07-25 | 2018-03-01 | Allergan, Inc. | Cyclosporin compositions |
US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
EP2197461B1 (fr) | 2007-10-08 | 2018-02-21 | Aurinia Pharmaceuticals Inc. | Compositions ophtalmiques comprenant des inhibiteurs de la calcineurine ou des inhibiteurs de mtor |
SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
US20110009339A1 (en) * | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
WO2010127301A1 (fr) * | 2009-05-01 | 2010-11-04 | Allergan, Inc. | Méthode de traitement de la conjonctivite allergique avec des compositions de cyclosporine |
US9017725B2 (en) * | 2009-06-09 | 2015-04-28 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
US20110294744A1 (en) * | 2010-05-25 | 2011-12-01 | Allergan, Inc. | Cyclosporin emulsions |
US20130029919A1 (en) * | 2011-07-26 | 2013-01-31 | Allergan, Inc. | Two part formulation system for opthalmic delivery |
US20130123194A1 (en) * | 2011-11-15 | 2013-05-16 | Allergan, Inc. | Autoclavable suspensions of cyclosporin a form 2 |
US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
HUE049489T2 (hu) * | 2011-12-07 | 2020-09-28 | Allergan Inc | Hatékony lipidbevitel emberi könnyfilmbe sóérzékeny emulziós rendszer alkalmazásával |
FR2988297B1 (fr) * | 2012-03-22 | 2014-03-28 | Thea Lab | Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur |
WO2013181339A2 (fr) | 2012-06-01 | 2013-12-05 | Allergan, Inc. | Analogues de cyclosporine a |
WO2014074605A1 (fr) * | 2012-11-08 | 2014-05-15 | Allergan, Inc. | Formulations topiques conservées ayant une activité antimicrobienne améliorée |
US10279005B2 (en) | 2014-11-25 | 2019-05-07 | Allergan, Inc. | Stabilized omega-3 ophthalmic compositions |
WO2016112321A1 (fr) | 2015-01-08 | 2016-07-14 | Allergan, Inc. | Dérivés de cyclosporine dans lesquels la chaîne latérale mebmt a été cyclisée |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
JP2020152674A (ja) * | 2019-03-20 | 2020-09-24 | 株式会社リコー | 難水溶性化合物の可溶化物の製造方法 |
GR1010012B (el) * | 2020-05-12 | 2021-05-27 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU205861B (en) * | 1986-12-19 | 1992-07-28 | Sandoz Ag | Process for producing hydrosole of pharmaceutically effective material |
JP2577049B2 (ja) * | 1987-06-04 | 1997-01-29 | 三共株式会社 | シクロスポリン製剤 |
US5540931A (en) | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
US5294604A (en) | 1989-12-20 | 1994-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating ocular diseases by periocular administration of cyclosporine A or G |
JPH0558906A (ja) * | 1991-09-06 | 1993-03-09 | Sankyo Co Ltd | シクロスポリン点眼製剤 |
JP3631490B2 (ja) | 1992-05-13 | 2005-03-23 | ノバルティス ファーマ株式会社 | シクロスポリン含有眼科用組成物 |
US5474979A (en) * | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
US5565302A (en) * | 1995-04-21 | 1996-10-15 | W. R. Grace & Co.-Conn. | Process for preparing photosensitive resin composition |
US6008192A (en) | 1997-03-12 | 1999-12-28 | Abbott Laboratories | Hydrophilic binary systems for the administration of lipophilic compounds |
JP2000143542A (ja) * | 1998-11-10 | 2000-05-23 | Wakamoto Pharmaceut Co Ltd | 難溶性免疫抑制剤含有o/wエマルジョン製剤 |
TR200302105T4 (tr) * | 2000-04-07 | 2004-02-23 | Laboratoire Medidom S. A. | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. |
JP2004503593A (ja) * | 2000-07-14 | 2004-02-05 | アラーガン、インコーポレイテッド | 増大した溶解度を持つ治療活性成分を含む組成物 |
KR20020050135A (ko) | 2000-12-20 | 2002-06-26 | 조명재 | 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물 |
US6656460B2 (en) | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
IL162496A0 (en) | 2001-12-14 | 2005-11-20 | Jagotec Ag | Pharmaceutical compositions containing cyclosporin |
US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050059583A1 (en) * | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
US20050276867A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
KR101333923B1 (ko) | 2004-11-09 | 2013-11-27 | 노바갈리 파르마 에스 에이 | 안정된 양성 제타 전위를 가지는 안과용 수중유 유제 |
WO2006073786A2 (fr) | 2004-12-30 | 2006-07-13 | Bausch & Lomb Incorporated | Compositions opthalmiques comprenant un steroide et une cyclosporine pour le traitement de l'oeil sec |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
WO2007011880A2 (fr) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Neuro-protection/neuro-stimulation oculaire amelioree |
US7501393B2 (en) * | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
CN101355876B (zh) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | 一种适用于眼部给药的组合物 |
US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
-
2007
- 2007-07-20 US US11/781,095 patent/US9561178B2/en active Active
- 2007-07-23 EP EP07799758.3A patent/EP2043602B1/fr active Active
- 2007-07-23 KR KR1020097003774A patent/KR20090053797A/ko not_active Application Discontinuation
- 2007-07-23 JP JP2009521925A patent/JP2009544722A/ja active Pending
- 2007-07-23 WO PCT/US2007/074079 patent/WO2008014200A2/fr active Application Filing
- 2007-07-23 MX MX2009000843A patent/MX2009000843A/es not_active Application Discontinuation
- 2007-07-23 BR BRPI0714727-9A patent/BRPI0714727A2/pt not_active IP Right Cessation
- 2007-07-23 AU AU2007276815A patent/AU2007276815B2/en not_active Ceased
- 2007-07-23 CA CA002658518A patent/CA2658518A1/fr not_active Abandoned
- 2007-07-23 EP EP16174365.3A patent/EP3124037A1/fr not_active Withdrawn
-
2008
- 2008-02-22 US US12/035,698 patent/US20080207495A1/en not_active Abandoned
-
2009
- 2009-01-19 IL IL196591A patent/IL196591A0/en unknown
- 2009-01-20 NO NO20090305A patent/NO20090305L/no not_active Application Discontinuation
-
2013
- 2013-09-05 JP JP2013184232A patent/JP2014015471A/ja active Pending
-
2016
- 2016-01-07 JP JP2016002022A patent/JP2016106103A/ja active Pending
-
2017
- 2017-02-06 US US15/425,836 patent/US20170143792A1/en not_active Abandoned
- 2017-03-22 JP JP2017055846A patent/JP2017132790A/ja active Pending
-
2019
- 2019-03-05 JP JP2019039610A patent/JP2019108380A/ja active Pending
-
2020
- 2020-10-07 US US17/064,988 patent/US20210169971A1/en not_active Abandoned
-
2021
- 2021-02-12 JP JP2021020702A patent/JP2021075564A/ja active Pending
-
2022
- 2022-05-12 US US17/663,188 patent/US20220409693A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2658518A1 (fr) | 2008-01-31 |
AU2007276815B2 (en) | 2013-05-09 |
JP2017132790A (ja) | 2017-08-03 |
US20080207495A1 (en) | 2008-08-28 |
KR20090053797A (ko) | 2009-05-27 |
EP2043602A2 (fr) | 2009-04-08 |
JP2009544722A (ja) | 2009-12-17 |
US20170143792A1 (en) | 2017-05-25 |
US20080039378A1 (en) | 2008-02-14 |
BRPI0714727A2 (pt) | 2013-05-14 |
WO2008014200A2 (fr) | 2008-01-31 |
US20220409693A1 (en) | 2022-12-29 |
EP3124037A1 (fr) | 2017-02-01 |
MX2009000843A (es) | 2009-02-03 |
WO2008014200A3 (fr) | 2008-08-28 |
JP2014015471A (ja) | 2014-01-30 |
JP2016106103A (ja) | 2016-06-16 |
AU2007276815A1 (en) | 2008-01-31 |
JP2021075564A (ja) | 2021-05-20 |
US9561178B2 (en) | 2017-02-07 |
EP2043602B1 (fr) | 2016-06-15 |
JP2019108380A (ja) | 2019-07-04 |
IL196591A0 (en) | 2009-11-18 |
US20210169971A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090305L (no) | Cyklosporin formuleringer | |
CY1123739T1 (el) | Αντισωματα anti-cd38 | |
TW200716646A (en) | (S)-N-methylnaltrexone | |
NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
NO20084893L (no) | Lyofiliserte terapeutiske peptistoffpreparater | |
MX2009004883A (es) | Piridil sulfoximinas multi-substituidas y su uso como insecticidas. | |
BRPI0718146A2 (pt) | Dispositivos de infusão e métodos | |
MA32161B1 (fr) | Formes de rifaximine et utilisations de celles-ci | |
NO20085396L (no) | Antistoffer og immunkonjugater, og anvendelser derav | |
MY148635A (en) | Anti-tat226 antibodies and immunoconjugates | |
MX2010003045A (es) | Composiciones de ciclosporina. | |
DK2040702T3 (da) | Anvendelse af AMPK-aktiverende imidazolderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater omfattende dem | |
NO20092052L (no) | Antistoffer og immunkonjugater, og anvendelser derav | |
EA201270722A1 (ru) | Формы рифаксимина и их применение | |
DK2273975T3 (da) | Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser | |
BRPI0508894A (pt) | meios para administração transdérmica de nicotina e uso | |
ATE474617T1 (de) | Medizinproduktsysteme | |
DK2049525T3 (da) | N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf | |
MY191407A (en) | Certain chemical entities, compositions and methods | |
NO20080068L (no) | Topisk unguale formuleringer | |
NO20085338L (no) | Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav | |
MX2007007613A (es) | Formulaciones farmaceuticas. | |
MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
NO20090458L (no) | Sukkerfrie, lagringsstabile antihistaminsaftpreparater | |
ATE490967T1 (de) | 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |